Advertisement

Topics

Galapagos nv Company Profile

13:53 EST 13th December 2018 | BioPortfolio

Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs with service activities. The joint venture operated until 2002 when the Company raised €23.4 million in a private placement. In May 2005, the Company raised €22.4 million through its initial public offering on the Euronext Brussels (Ticker symbol: GLPG) and Euronext Amsterdam (GLPGA) stock exchanges. In October 2005, Galapagos acquired BioFocus, a drug discovery company based in Saffron Walden, UK, through an all share offer, giving BioFocus shareholders a 29% state holding in the enlarged Company. On October 20, 2005 Galapagos started trading on the Alternative Investment Market of the London Stock exchange (Ticker symbol: GLPG). On June 13, 2006 Galapagos announced the acquisition of the drug discovery operations of Discovery Partners International, forming the new drug discovery division called BioFocus DPI.

Location

Industriepark Mechelen Noord Generaal De Wittelaan L11 A3
Mechelen
B-2800
Belgium

Contact

Phone: 32 15 34 29 00
Fax: 32 15 34 29 01
Email: bd@glpg.com


News Articles [164 Associated News Articles listed on BioPortfolio]

Galapagos: 3 Pillars to Success, The Galapagos Model

In this episode of PharmaTelevision News Review,filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to Onno Van De Stolpe, CEO of Galapagos

Galapagos: Technology Platforms and Future Plans

In this episode of PharmaTelevision News Review, Fintan Walton talks with Onno Van de Stolpe, CEO at Galapagos. Filmed at BioBusiness 2010 in London, England, they discuss: • How Galapagos has handl...

Galapagos NV: Galapagos announces launch of proposed public offering

Mechelen, Belgium, 12 September 2018, 22.45 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it intends to offer and sell, subject to market and other condi...

Galapagos NV: Galapagos and AbbVie restructure CF collaboration

Mechelen, Belgium, Chicago, US; 24 October 2018; 22.02 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) and AbbVie, Inc (NYSE: ABBV) announce a restructuring of their cystic fib...

Galapagos NV: Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Mechelen, Belgium and Planegg/Munich, Germany; 13 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announc...

Galapagos NV: MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Mechelen, Belgium and Planegg/Munich, Germany; 12 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announc...

Galapagos: Onno van de Stolpe, CEO

Onno van de Stolpe talks to Fintan Walton, about Galapagos' current business model and overall strategic outlook. They discuss the integration of BioFocus following its acquisition by Galapagos in Nov...

Galapagos NV: Galapagos raises $300 million gross proceeds in a U.S. public offering

Mechelen, Belgium, 13 September 2018, 03.00 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today the pricing of its U.S. public offering totaling $300 million gross ...

Drugs and Medications [0 Results]

None

PubMed Articles [12 Associated PubMed Articles listed on BioPortfolio]

Intestinal parasites in Galapagos sea lions (Zalophus wollebaeki) Sivertsen, 1953 on San Cristóbal Island, Galápagos, Ecuador.

Knowledge regarding endoparasites of Galapagos sea lions, Zalophus wollebaeki Sivertsen, 1953, is limited to 1 report. Herein, we examined feces extracted from the lower gastro-intestinal tract of 15 ...

EVALUATION OF THE OPHTHALMIC DISEASE AND HISTOPATHOLOGIC EFFECTS DUE TO THE OCULAR TREMATODE PHILOPHTHALMUS ZALOPHI ON JUVENILE GALAPAGOS SEA LIONS ( ZALOPHUS WOLLEBAEKI).

The Galapagos sea lion ( Zalophus wollebaeki) is an otariid species endemic to the Galapagos archipelago and is currently listed as endangered. The ocular trematode Philophthalmus zalophi was recently...

Genome-wide assessment of diversity and divergence among extant Galapagos giant tortoise species.

Genome-wide assessments allow for fuller characterization of genetic diversity, finer-scale population delineation, and better detection of demographically significant units to guide conservation comp...

Burden of exposure to infectious bursal disease virus, infectious bronchitis virus, Newcastle disease virus, Mycoplasma gallisepticum, and intestinal parasites in introduced broiler chickens on the Galapagos.

Diseases in introduced broilers can possibly spill over to wild birds on the Galapagos. Knowledge about the current burden of exposure to pathogens in broilers on the Galapagos is very limited. The ob...

El Niño drives a widespread ulcerative skin disease outbreak in Galapagos marine fishes.

Climate change increases local climatic variation and unpredictability, which can alter ecological interactions and trigger wildlife disease outbreaks. Here we describe an unprecedented multi-species ...

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Galapagos nv

Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs...

Discovery Partners International

Discovery Partners recently completed the sale of all of the stock of Discovery Partners’ operating subsidiaries and all of Discovery Partners’ material operating assets pursuant to a stock and as...

Galapagos

We are a genomics based drug discovery company, that has drug discovery programs based on proprietary disease modifying drug targets. Our vision is to bring novel drugs to the market in selected disea...

More Information about "Galapagos nv" on BioPortfolio

We have published hundreds of Galapagos nv news stories on BioPortfolio along with dozens of Galapagos nv Clinical Trials and PubMed Articles about Galapagos nv for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Galapagos nv Companies in our database. You can also find out about relevant Galapagos nv Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record